Cargando…
ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery c...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305089/ https://www.ncbi.nlm.nih.gov/pubmed/35377938 http://dx.doi.org/10.1182/blood.2021014240 |
_version_ | 1784752239338848256 |
---|---|
author | Karnes, Jason H. Rollin, Jerome Giles, Jason B. Martinez, Kiana L. Steiner, Heidi E. Shaffer, Christian M. Momozawa, Yukihide Inai, Chihiro Bombin, Andrei Shi, Mingjian Mosley, Jonathan D. Stanaway, Ian Selleng, Kathleen Thiele, Thomas Mushiroda, Taisei Pouplard, Claire Heddle, Nancy M. Kubo, Michiaki Phillips, Elizabeth J. Warkentin, Theodore E. Gruel, Yves Greinacher, Andreas Roden, Dan M. |
author_facet | Karnes, Jason H. Rollin, Jerome Giles, Jason B. Martinez, Kiana L. Steiner, Heidi E. Shaffer, Christian M. Momozawa, Yukihide Inai, Chihiro Bombin, Andrei Shi, Mingjian Mosley, Jonathan D. Stanaway, Ian Selleng, Kathleen Thiele, Thomas Mushiroda, Taisei Pouplard, Claire Heddle, Nancy M. Kubo, Michiaki Phillips, Elizabeth J. Warkentin, Theodore E. Gruel, Yves Greinacher, Andreas Roden, Dan M. |
author_sort | Karnes, Jason H. |
collection | PubMed |
description | Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery cohort of patients divided into 3 groups: (1) functional assay-positive cases (n = 1269), (2) antibody-positive (functional assay-negative) controls (n = 1131), and (3) antibody-negative controls (n = 1766). Significant associations (α = 5 × 10(−8)) were investigated in a replication cohort (α = 0.05) of functional assay-confirmed HIT cases (n = 177), antibody-positive (function assay-negative) controls (n = 258), and antibody-negative controls (n = 351). We observed a strong association for positive functional assay with increasing PF4/heparin immunoglobulin-G (IgG) level (odds ratio [OR], 16.53; 95% confidence interval [CI], 13.83-19.74; P = 1.51 × 10(−209)) and female sex (OR, 1.15; 95% CI, 1.01-1.32; P = .034). The rs8176719 C insertion variant in ABO was significantly associated with positive functional assay status in the discovery cohort (frequency = 0.41; OR, 0.751; 95% CI, 0.682-0.828; P = 7.80 × 10(−9)) and in the replication cohort (OR, 0.467; 95% CI, 0.228-0.954; P = .0367). The rs8176719 C insertion, which encodes all non-O blood group alleles, had a protective effect, indicating that the rs8176719 C deletion and the O blood group were risk factors for HIT (O blood group OR, 1.42; 95% CI, 1.26-1.61; P = 3.09 × 10(−8)). Meta-analyses indicated that the ABO association was independent of PF4/heparin IgG levels and was stronger when functional assay-positive cases were compared with antibody-positive (functional assay-negative) controls than with antibody-negative controls. Sequencing and fine-mapping of ABO demonstrated that rs8176719 was the causal single nucleotide polymorphism (SNP). Our results clarify the biology underlying HIT pathogenesis with ramifications for prediction and may have important implications for related conditions, such as vaccine-induced thrombotic thrombocytopenia. |
format | Online Article Text |
id | pubmed-9305089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-93050892022-11-16 ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia Karnes, Jason H. Rollin, Jerome Giles, Jason B. Martinez, Kiana L. Steiner, Heidi E. Shaffer, Christian M. Momozawa, Yukihide Inai, Chihiro Bombin, Andrei Shi, Mingjian Mosley, Jonathan D. Stanaway, Ian Selleng, Kathleen Thiele, Thomas Mushiroda, Taisei Pouplard, Claire Heddle, Nancy M. Kubo, Michiaki Phillips, Elizabeth J. Warkentin, Theodore E. Gruel, Yves Greinacher, Andreas Roden, Dan M. Blood Thrombosis and Hemostasis Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery cohort of patients divided into 3 groups: (1) functional assay-positive cases (n = 1269), (2) antibody-positive (functional assay-negative) controls (n = 1131), and (3) antibody-negative controls (n = 1766). Significant associations (α = 5 × 10(−8)) were investigated in a replication cohort (α = 0.05) of functional assay-confirmed HIT cases (n = 177), antibody-positive (function assay-negative) controls (n = 258), and antibody-negative controls (n = 351). We observed a strong association for positive functional assay with increasing PF4/heparin immunoglobulin-G (IgG) level (odds ratio [OR], 16.53; 95% confidence interval [CI], 13.83-19.74; P = 1.51 × 10(−209)) and female sex (OR, 1.15; 95% CI, 1.01-1.32; P = .034). The rs8176719 C insertion variant in ABO was significantly associated with positive functional assay status in the discovery cohort (frequency = 0.41; OR, 0.751; 95% CI, 0.682-0.828; P = 7.80 × 10(−9)) and in the replication cohort (OR, 0.467; 95% CI, 0.228-0.954; P = .0367). The rs8176719 C insertion, which encodes all non-O blood group alleles, had a protective effect, indicating that the rs8176719 C deletion and the O blood group were risk factors for HIT (O blood group OR, 1.42; 95% CI, 1.26-1.61; P = 3.09 × 10(−8)). Meta-analyses indicated that the ABO association was independent of PF4/heparin IgG levels and was stronger when functional assay-positive cases were compared with antibody-positive (functional assay-negative) controls than with antibody-negative controls. Sequencing and fine-mapping of ABO demonstrated that rs8176719 was the causal single nucleotide polymorphism (SNP). Our results clarify the biology underlying HIT pathogenesis with ramifications for prediction and may have important implications for related conditions, such as vaccine-induced thrombotic thrombocytopenia. American Society of Hematology 2022-07-21 /pmc/articles/PMC9305089/ /pubmed/35377938 http://dx.doi.org/10.1182/blood.2021014240 Text en © 2022 by The American Society of Hematology. https://creativecommons.org/licenses/by-nc-nd/4.0/Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
spellingShingle | Thrombosis and Hemostasis Karnes, Jason H. Rollin, Jerome Giles, Jason B. Martinez, Kiana L. Steiner, Heidi E. Shaffer, Christian M. Momozawa, Yukihide Inai, Chihiro Bombin, Andrei Shi, Mingjian Mosley, Jonathan D. Stanaway, Ian Selleng, Kathleen Thiele, Thomas Mushiroda, Taisei Pouplard, Claire Heddle, Nancy M. Kubo, Michiaki Phillips, Elizabeth J. Warkentin, Theodore E. Gruel, Yves Greinacher, Andreas Roden, Dan M. ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
title | ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
title_full | ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
title_fullStr | ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
title_full_unstemmed | ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
title_short | ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
title_sort | abo o blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia |
topic | Thrombosis and Hemostasis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305089/ https://www.ncbi.nlm.nih.gov/pubmed/35377938 http://dx.doi.org/10.1182/blood.2021014240 |
work_keys_str_mv | AT karnesjasonh aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT rollinjerome aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT gilesjasonb aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT martinezkianal aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT steinerheidie aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT shafferchristianm aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT momozawayukihide aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT inaichihiro aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT bombinandrei aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT shimingjian aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT mosleyjonathand aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT stanawayian aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT sellengkathleen aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT thielethomas aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT mushirodataisei aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT pouplardclaire aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT heddlenancym aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT kubomichiaki aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT phillipselizabethj aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT warkentintheodoree aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT gruelyves aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT greinacherandreas aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia AT rodendanm aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia |